blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3542803

EP3542803 - PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE FOR USE IN PREVENTING OR TREATING BREAST CANCER [Right-click to bookmark this link]
Former [2019/39]PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER INCLUDING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PRODUCING SAME
[2022/30]
StatusNo opposition filed within time limit
Status updated on  27.10.2023
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  18.11.2022
FormerGrant of patent is intended
Status updated on  07.07.2022
FormerRequest for examination was made
Status updated on  23.08.2019
FormerThe international publication has been made
Status updated on  25.05.2018
Most recent event   Tooltip05.07.2024Lapse of the patent in a contracting state
New state(s): MC		published on 07.08.2024  [2024/32]
Applicant(s)For all designated states
Chemas Co., Ltd.
3rd Fl.
502 Bongeunsa-ro
Gangnam-gu
Seoul 06163 / KR
[2019/39]
Inventor(s)01 / BAE, Ill Ju
242-19, Nunkkotmaeul-gil
Imgye-myeon
Jeongseon-gun Gangwon-do 26112 / KR
02 / LIAN, Zenglin
Rm 412 No.5 B/D Cuiweinanli
Cuiwei Road
Haidian District
Beijing 100036 / CN
 [2019/39]
Representative(s)Adam, Holger
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[2019/39]
Application number, filing date17872391.217.11.2017
[2019/39]
WO2017KR13148
Priority number, dateKR2016015522821.11.2016         Original published format: KR 20160155228
[2019/39]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018093215
Date:24.05.2018
Language:KO
[2018/21]
Type: A1 Application with search report 
No.:EP3542803
Date:25.09.2019
Language:EN
[2019/39]
Type: B1 Patent specification 
No.:EP3542803
Date:21.12.2022
Language:EN
[2022/51]
Search report(s)International search report - published on:KR24.05.2018
(Supplementary) European search report - dispatched on:EP17.06.2020
ClassificationIPC:A61K33/36, A61K31/285, A61P35/04, C01G28/00
[2020/29]
CPC:
A61P35/04 (EP,CN,IL,US); A61K33/36 (EP,CN,IL,KR,US); A61K31/285 (IL,KR);
A61P35/00 (CN); C01G28/00 (IL); C01G28/005 (EP,IL);
C01P2002/72 (EP,IL); C01P2002/77 (EP,IL); C01P2002/88 (EP);
C01P2006/80 (IL) (-)
Former IPC [2019/39]A61K33/36, A61K31/285
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/39]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EIN KRISTALLINES POLYMORPH VON TETRAARSENHEXOXID ZUR VERWENDUNG IN DER PRÄVENTION ODER BEHANDLUNG VON BRUSTKREBS[2022/30]
English:PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE FOR USE IN PREVENTING OR TREATING BREAST CANCER[2022/30]
French:COMPOSITION PHARMACEUTIQUE COMPRENANT UN POLYMORPHE CRISTALLIN D'HEXOXYDE TÉTRAARSENIQUE POUR L'UTILISATION DANS LA PRÉVENTION OU LE TRAITEMENT DU CANCER DU SEIN[2022/30]
Former [2019/39]PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VORBEUGUNG ODER BEHANDLUNG VON BRUSTKREBS, EINSCHLIESSLICH KRISTALLINEM POLYMORPH VON TETRAARSENHEXOXID UND VERFAHREN ZUR HERSTELLUNG DAVON
Former [2019/39]PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER INCLUDING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PRODUCING SAME
Former [2019/39]COMPOSITION PHARMACEUTIQUE DE PRÉVENTION OU DE TRAITEMENT DU CANCER DU SEIN COMPRENANT UN POLYMORPHE CRISTALLIN D'HEXOXYDE DE TÉTRAARSENIC, ET PROCÉDÉ DE PRODUCTION DE LADITE COMPOSITION
Entry into regional phase13.05.2019Translation filed 
13.05.2019National basic fee paid 
13.05.2019Search fee paid 
13.05.2019Designation fee(s) paid 
13.05.2019Examination fee paid 
Examination procedure13.05.2019Examination requested  [2019/39]
07.01.2021Amendment by applicant (claims and/or description)
08.07.2022Communication of intention to grant the patent
28.10.2022Fee for grant paid
28.10.2022Fee for publishing/printing paid
28.10.2022Receipt of the translation of the claim(s)
Opposition(s)22.09.2023No opposition filed within time limit [2023/48]
Fees paidRenewal fee
29.11.2019Renewal fee patent year 03
19.11.2020Renewal fee patent year 04
24.11.2021Renewal fee patent year 05
15.11.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.12.2022
AT21.12.2022
CZ21.12.2022
DK21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
IT21.12.2022
LT21.12.2022
LV21.12.2022
MC21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SI21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
IS21.04.2023
PT21.04.2023
[2024/32]
Former [2024/26]AL21.12.2022
AT21.12.2022
CZ21.12.2022
DK21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
IT21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SI21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
IS21.04.2023
PT21.04.2023
Former [2024/11]AL21.12.2022
AT21.12.2022
CZ21.12.2022
DK21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SI21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
IS21.04.2023
PT21.04.2023
Former [2023/46]AL21.12.2022
AT21.12.2022
CZ21.12.2022
DK21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
IS21.04.2023
PT21.04.2023
Former [2023/39]AL21.12.2022
AT21.12.2022
CZ21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
IS21.04.2023
PT21.04.2023
Former [2023/38]AL21.12.2022
AT21.12.2022
CZ21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
PL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SK21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
PT21.04.2023
Former [2023/37]AL21.12.2022
AT21.12.2022
CZ21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
PT21.04.2023
Former [2023/35]AT21.12.2022
CZ21.12.2022
EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
RO21.12.2022
RS21.12.2022
SE21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
PT21.04.2023
Former [2023/34]EE21.12.2022
ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
RS21.12.2022
SE21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
PT21.04.2023
Former [2023/33]ES21.12.2022
FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
RS21.12.2022
SE21.12.2022
SM21.12.2022
NO21.03.2023
GR22.03.2023
Former [2023/29]FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
NL21.12.2022
RS21.12.2022
SE21.12.2022
NO21.03.2023
GR22.03.2023
Former [2023/25]FI21.12.2022
HR21.12.2022
LT21.12.2022
LV21.12.2022
RS21.12.2022
SE21.12.2022
NO21.03.2023
GR22.03.2023
Former [2023/23]FI21.12.2022
LT21.12.2022
LV21.12.2022
SE21.12.2022
NO21.03.2023
GR22.03.2023
Former [2023/22]FI21.12.2022
LT21.12.2022
SE21.12.2022
NO21.03.2023
Former [2023/20]LT21.12.2022
NO21.03.2023
Documents cited:Search[I]US2002028253  (BAE ILL-JU [KR], et al) [I] 1-5 * abstract * * column 1, paragraph 2 * * figure 1 * * tables 1,2 * * examples 1,2 * * example 3 * * table 5 * * examples 4,5 * * example 7 * * example 8 * * example 11 *;
 [I]  - MIN JEONG KIM ET AL, "Arsenic hexoxide enhances TNF-[alpha]-induced anticancer effects by inhibiting NF-[kappa]B activity at a safe dose in MCF-7 human breast cancer cells", ONCOLOGY REPORTS, (20140501), vol. 31, no. 5, doi:10.3892/or.2014.3085, ISSN 1021-335X, pages 2305 - 2311, XP055701073 [I] 1-5 * the whole document * * page 2306, column l, paragraph 2 * * page 2307, column l, paragraph 2 * * page 2310, column r, paragraph 3 *

DOI:   http://dx.doi.org/10.3892/or.2014.3085
 [A]  - WON SUP LEE ET AL, "Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF-[kappa]B activity in SW620 human colon cancer cells", ONCOLOGY REPORTS, (20150601), vol. 33, no. 6, doi:10.3892/or.2015.3890, ISSN 1021-335X, pages 2940 - 2946, XP055701054 [A] 1-5 * the whole document *

DOI:   http://dx.doi.org/10.3892/or.2015.3890
International search[XA]KR100272835B  (BAE IL JU [KR]) [X] 1, 3-5 * See examples 1, 2, 1]; and claim 1. * [A] 2;
 [A]KR20040014813  (BAE IL JU, et al) [A] 1-5* See the entire document. *;
 [A]KR20100054210  (CHONJISAN CO LTD [KR]) [A] 1-5 * See the entire document. *;
 [A]KR20100069204  (CHONJISAN CO LTD [KR]) [A] 1-5 * See the entire document. *;
 [A]KR20130110466  (OK KYOUNG YUN [KR], et al) [A] 1-5 * See the entire document. *
by applicantKR100272835B
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.